Building a retirement portfolio of $1 million or more is within reach for many Americans. The primary things you'll need are time and money to invest.
American stocks have crashed this year as concerns about Donald Trump tariffs rose. The top blue-chip indices like the Dow Jones, Nasdaq 100, and S&P 500 have all moved into a correction as recession odds have soared.
Investing in stocks comes with risks. There's no way around that fact.
AbbVie and Sanofi occupy leading positions in the global immunology market. Each of them has advantages, as well as dark spots in the pipeline of drugs relative to the rival. In this article you will discover whether Sanofi or AbbVie is a more promising stock in the long term.
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list.
The latest trading day saw AbbVie (ABBV) settling at $209.17, representing a -0.4% change from its previous close.
AbbVie Inc. NYSE: ABBV is trading near an all-time high after the company announced a licensing agreement with Gubra, a Danish company. The agreement pertains to Gubra's experimental weight loss drug, which is in a Phase 1 trial.
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.
So, you want to invest in AbbVie (ABBV 0.14%) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy?
You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of Retirement and Disability Policy says Social Security's funds might run out by 2037, which could cut benefits to about 76% of what people get now.